| Tepotinib studied in …STUDIED_INderived22 of 22show fewer |
|---|
| → studied in | NCT07619339Phase 1 · recruiting A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer · 22 trials list this drug (9 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06083857Phase 1/Phase 2 · active not recruiting PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer · 22 trials list this drug (9 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06106802Phase 2 · recruiting Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment · 22 trials list this drug (9 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03940703Phase 2 · completed A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) · 22 trials list this drug (9 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02864992Phase 2 · active not recruiting Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) · 22 trials list this drug (9 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06031688Phase 2 · recruiting Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) · 22 trials list this drug (9 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05782361Phase 1 · active not recruiting POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC · 22 trials list this drug (9 active) | — | — | Malignant Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06908993Phase 3 · recruiting Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated · 22 trials list this drug (9 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05159245Phase 2 · recruiting The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs · 22 trials list this drug (9 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05120960Phase 1 · withdrawn A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors · 22 trials list this drug (9 active) | — | — | Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 22 trials list this drug (9 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739358Phase 1/Phase 2 · terminated CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC · 22 trials list this drug (9 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 22 trials list this drug (9 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03492437Phase 1 · completed Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate · 22 trials list this drug (9 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03531762Phase 1 · completed Effect of a Proton Pump Inhibitor on the PK of Tepotinib · 22 trials list this drug (9 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04515394Phase 2 · terminated Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) · 22 trials list this drug (9 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01982955Phase 1/Phase 2 · completed Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) · 22 trials list this drug (9 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01014936Phase 1 · completed First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors · 22 trials list this drug (9 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01988493Phase 1/Phase 2 · completed Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma · 22 trials list this drug (9 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02115373Phase 1/Phase 2 · completed c-Met Second-Line Hepatocellular Carcinoma · 22 trials list this drug (9 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04647838Phase 2 · unknown Tepotinib in Solid Tumors Harboring MET Alterations · 22 trials list this drug (9 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01832506Phase 1 · completed A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors · 22 trials list this drug (9 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |